Wistar Wire: Melanoma

glester
Amanpreet Kaur, a student in the Cancer Biology Ph.D. program, a joint venture between Wistar and University of the Sciences, was recently awarded at $10,000 grant by the Joanna M. Nicolay Melanoma Foundation. Kaur, who studies in the laboratory of her mentor, Wistar Assistant Professor Ashani Weeraratna, Ph.D., will use the money to further her work on protein receptors that play an important role in melanoma progression and therapy resistance.
Events, Funding, Melanoma
wistar
It may not seem like it, but the winter sun still packs a punch, especially when it comes to melanoma, an aggressive form of skin cancer. “There’s a saying we like to use: ‘Melanoma doesn’t hibernate.’ So just because it’s cold outside does not mean sun exposure can’t be dangerous,” said Ashani Weeraratna, Ph.D.
Cancer, Melanoma
wistar
A BRAF inhibitor known as vemurafenib (Zelboraf) has been touted as a breakthrough melanoma treatment. But for some patients, the price of success is a mutation that leads to the development of secondary skin cancers called squamous cell carcinomas. In an editorial in The New England Journal of Medicine, Wistar researcher Ashani Weeraratna, Ph.D., discusses the success of a new combination treatment.
Cancer, Genes, Melanoma
wistar
On the heels of announcing findings that could change the way melanoma is treated, Wistar announced a new effort that will change the way scientists conduct melanoma research...
Cancer, Melanoma